Expanding the utility of the ROX index among patients with acute hypoxemic respiratory failure

PLoS One. 2022 Apr 26;17(4):e0261234. doi: 10.1371/journal.pone.0261234. eCollection 2022.

Abstract

Background: Delaying intubation in patients who fail high-flow nasal cannula (HFNC) may result in increased mortality. The ROX index has been validated to predict HFNC failure among pneumonia patients with acute hypoxemic respiratory failure (AHRF), but little information is available for non-pneumonia causes. In this study, we validate the ROX index among AHRF patients due to both pneumonia or non-pneumonia causes, focusing on early prediction.

Methods: This was a retrospective observational study in eight Singapore intensive care units from 1 January 2015 to 30 September 2017. All patients >18 years who were treated with HFNC for AHRF were eligible and recruited. Clinical parameters and arterial blood gas values at HFNC initiation and one hour were recorded. HFNC failure was defined as requiring intubation post-HFNC initiation.

Results: HFNC was used in 483 patients with 185 (38.3%) failing HFNC. Among pneumonia patients, the ROX index was most discriminatory in pneumonia patients one hour after HFNC initiation [AUC 0.71 (95% CI 0.64-0.79)], with a threshold value of <6.06 at one hour predicting HFNC failure (sensitivity 51%, specificity 80%, positive predictive value 61%, negative predictive value 73%). The discriminatory power remained moderate among pneumonia patients upon HFNC initiation [AUC 0.65 (95% CI 0.57-0.72)], non-pneumonia patients at HFNC initiation [AUC 0.62 (95% CI 0.55-0.69)] and one hour later [AUC 0.63 (95% CI 0.56-0.70)].

Conclusion: The ROX index demonstrated moderate discriminatory power among patients with either pneumonia or non-pneumonia-related AHRF at HFNC initiation and one hour later.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cannula / adverse effects
  • Humans
  • Noninvasive Ventilation* / adverse effects
  • Oxygen Inhalation Therapy / adverse effects
  • Pneumonia* / complications
  • Pneumonia* / therapy
  • Respiratory Insufficiency* / etiology
  • Respiratory Insufficiency* / therapy
  • Respiratory Rate

Grants and funding

Author KCS has received honoraria and travel support from Medtronic and GE Healthcare. MC acknowledges travel support and honorarium from Baxter and Medtronic. JP and KR have received travel support from Medtronic. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.